Request Demo
Last update 15 May 2025
Prostate cancer vaccine(Onyvax Ltd.)
Last update 15 May 2025
Overview
Basic Info
Drug Type Therapeutic vaccine |
Synonyms ONY-P, Onyvax-P, Prostate cancer vaccine + [2] |
Target- |
Action stimulants |
Mechanism Immunostimulants |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
1
Clinical Trials associated with Prostate cancer vaccine(Onyvax Ltd.)EUCTR2006-001619-31-EE
A PHASE IIB TRIAL TO DETERMINE THE EFFICACY AND SAFETY OF ONY-P VACCINES IN THE MANAGEMENT OF PROSTATE CANCER WITHOUT DETECTABLE METASTASES FOLLOWING INITIAL ESCAPE FROM HORMONE TREATMENT - THE TREATMENT OF ADVANCED PROSTATE CANCER USING DISABLED CANCER CELLS AS VACCINES
100 Clinical Results associated with Prostate cancer vaccine(Onyvax Ltd.)
Login to view more data
100 Translational Medicine associated with Prostate cancer vaccine(Onyvax Ltd.)
Login to view more data
100 Patents (Medical) associated with Prostate cancer vaccine(Onyvax Ltd.)
Login to view more data
1
Literatures (Medical) associated with Prostate cancer vaccine(Onyvax Ltd.)01 Oct 2005Current opinion in molecular therapeutics
Technology evaluation: Onyvax-P, Onyvax.
Review
Author: Böhmer, Torsten ; Doehn, Christian ; Jocham, Dieter
Onyvax is developing Onyvax-P, an allogeneic whole-cell vaccine, for the potential treatment of prostate cancer. The vaccine is currently undergoing phase II clinical trials.
100 Deals associated with Prostate cancer vaccine(Onyvax Ltd.)
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Prostatic Cancer | Phase 2 | United States | 01 Mar 2007 | |
| Prostatic Cancer | Phase 2 | United States | 01 Mar 2007 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 2 | 20 | wlgfxgdjrn(qrywxpdrxf) = A statistically significant sustained PSA velocity reduction was seen in 3 patients (23%) ytztsgxtwa (rgxjwcpjki ) | - | 01 Jun 2005 |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free